DOI QR코드

DOI QR Code

Effect of isoflavone-enriched whole soy milk powder supplementation on bone metabolism in ovariectomized mice

  • Kim, So Mi (Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University) ;
  • Lee, Hyun Sook (Department of Food Science & Nutrition, Dongseo University) ;
  • Jung, Jae In (Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University) ;
  • Lim, Su-Min (Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University) ;
  • Lim, Ji Hoon (Institute of Food Processing Technology, Uwell Bio Co. Ltd.) ;
  • Ha, Wang-Hyun (Institute of Food Processing Technology, Uwell Bio Co. Ltd.) ;
  • Jeon, Chang Lae (Institute of Food Processing Technology, Uwell Bio Co. Ltd.) ;
  • Lee, Jae-Yong (Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University) ;
  • Kim, Eun Ji (Center for Efficacy Assessment and Development of Functional Foods and Drugs, Hallym University)
  • Received : 2018.02.14
  • Accepted : 2018.05.02
  • Published : 2018.08.01

Abstract

BACKGROUND/OBJECTIVE: There is intense interest in soy isoflavone as a hormone replacement therapy for the prevention of postmenopausal osteoporosis. A new kind of isoflavone-enriched whole soy milk powder (I-WSM) containing more isoflavones than conventional whole soy milk powder was recently developed. The aim of this study was to investigate the effects of I-WSM on bone metabolism in ovariectomized mice. MATERIALS/METHODS: Sixty female ICR mice individually underwent ovariectomy (OVX) or a sham operation, and were randomized into six groups of 10 animals each as follows: Sham, OVX, OVX with 2% I-WSM diet, OVX with 10% I-WSM diet, OVX with 20% I-WSM diet, and OVX with 20% WSM diet. After an 8-week treatment period, bone mineral density (BMD), calcium, alkaline phosphatase (ALP), tartrate-resistant acid phosphatase (TRAP) 5b, osteocalcin (OC), procollagen 1 N-terminal propeptide (P1NP), and osteoprotegenin (OPG) were analyzed. RESULTS: BMD was significantly lower in the OVX group compared to the Sham group but was significantly higher in OVX + 10% I-WSM and OVX + 20% I-WSM groups compared to the OVX group (P < 0.05). Serum calcium concentration significantly increased in the OVX + 10% and 20% I-WSM groups. Serum ALP levels were significantly lower in the OVX + 10% and 20% I-WSM groups compared to the other experimental groups (P < 0.05). OC was significantly reduced in the OVX group compared to the Sham group (P < 0.05), but a dose-dependent increase was observed in the OVX groups supplemented with I-WSM. P1NP and OPG levels were significantly reduced, while TRAP 5b level was significantly elevated in the OVX group compared with the Sham group, which was not affected by I-WSM (P < 0.05). CONCLUSIONS: This study suggests that I-WSM supplementation in OVX mice has the effect of preventing BMD reduction and promoting bone formation. Therefore, I-WSM can be used as an effective alternative to postmenopausal osteoporosis prevention.

Keywords

References

  1. Lecart MP, Reginster JY. Current options for the management of postmenopausal osteoporosis. Expert Opin Pharmacother 2011;12: 2533-52. https://doi.org/10.1517/14656566.2011.618123
  2. Seckin B, Pekcan MK, Inal HA, Gulerman C. The relationship between breast density and bone mineral density in never users of postme- nopausal hormone therapy. Aging Clin Exp Res 2017;29:537-41. https://doi.org/10.1007/s40520-016-0599-1
  3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C,Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33. https://doi.org/10.1001/jama.288.3.321
  4. Gambacciani M, Levancini M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Prz Menopauzalny 2014;13:213-20.
  5. Qi S, Zheng H. Combined effects of phytoestrogen genistein and silicon on ovariectomy-induced bone loss in rat. Biol Trace Elem Res 2017;177:281-7. https://doi.org/10.1007/s12011-016-0882-1
  6. Pilsakova L, Riecansky I, Jagla F. The physiological actions of isoflavone phytoestrogens. Physiol Res 2010;59:651-64.
  7. Vitale DC, Piazza C, Melilli B, Drago F, Salomone S. Isoflavones: estrogenic activity, biological effect and bioavailability. Eur J Drug Metab Pharmacokinet 2013;38:15-25. https://doi.org/10.1007/s13318-012-0112-y
  8. Moutsatsou P. The spectrum of phytoestrogens in nature: our knowledge is expanding. Hormones (Athens) 2007;6:173-93.
  9. Cos P, De Bruyne T, Apers S, Vanden Berghe D, Pieters L, Vlietinck AJ. Phytoestrogens: recent developments. Planta Med 2003;69: 589-99. https://doi.org/10.1055/s-2003-41122
  10. Huang HY, Yang HP, Yang HT, Yang TC, Shieh MJ, Huang SY. One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. J Nutr Biochem 2006;17:509-17. https://doi.org/10.1016/j.jnutbio.2006.01.003
  11. Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 2001;86: 5217-21. https://doi.org/10.1210/jcem.86.11.8040
  12. Zhang X, Shu XO, Li H, Yang G, Li Q, Gao YT, Zheng W. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med 2005;165:1890-5. https://doi.org/10.1001/archinte.165.16.1890
  13. Kim MS, Lee YS. Effects of soy isoflavone and/or estrogen treatments on bone metabolism in ovariectomized rats. J Med Food 2005;8:439-45. https://doi.org/10.1089/jmf.2005.8.439
  14. Bitto A, Burnett BP, Polito F, Marini H, Levy RM, Armbruster MA, Minutoli L, Di Stefano V, Irrera N, Antoci S, Granese R, Squadrito F, Altavilla D. Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and estradiol. Br J Pharmacol 2008;155:896-905. https://doi.org/10.1038/bjp.2008.305
  15. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295: 2057-71. https://doi.org/10.1001/jama.295.17.2057
  16. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-25. https://doi.org/10.1172/JCI27071
  17. Bergh JJ, Xu Y, Farach-Carson MC. Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. Endocrinology 2004;145:426-36. https://doi.org/10.1210/en.2003-0319
  18. Klepzig M, Jonas D, Oremek GM. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma. Anticancer Res 2009;29:671-3.
  19. Ljusberg J, Wang Y, Lang P, Norgard M, Dodds R, Hultenby K, Ek-Rylander B, Andersson G. Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem 2005;280:28370-81. https://doi.org/10.1074/jbc.M502469200
  20. Campbell SE, Febbraio MA. Effects of ovarian hormones on exercise metabolism. Curr Opin Clin Nutr Metab Care 2001;4:515-20. https://doi.org/10.1097/00075197-200111000-00009
  21. Misso ML, Jang C, Adams J, Tran J, Murata Y, Bell R, Boon WC, Simpson ER, Davis SR. Differential expression of factors involved in fat metabolism with age and the menopause transition. Maturitas 2005;51:299-306. https://doi.org/10.1016/j.maturitas.2004.08.013
  22. Huang S, Chen JC, Hsu CW, Chang WH. Effects of nano calcium carbonate and nano calcium citrate on toxicity in ICR mice and on bone mineral density in an ovariectomized mice model. Nanotechnology 2009;20:375102. https://doi.org/10.1088/0957-4484/20/37/375102
  23. Zoth N, Weigt C, Laudenbach-Leschowski U, Diel P. Physical activity and estrogen treatment reduce visceral body fat and serum levels of leptin in an additive manner in a diet induced animal model of obesity. J Steroid Biochem Mol Biol 2010;122:100-5. https://doi.org/10.1016/j.jsbmb.2010.03.029
  24. Zheng W, Rogoschin J, Niehoff A, Oden K, Kulling SE, Xie M, Diel P. Combinatory effects of phytoestrogens and exercise on body fat mass and lipid metabolism in ovariectomized female rats. J Steroid Biochem Mol Biol 2018;178:73-81. https://doi.org/10.1016/j.jsbmb.2017.11.002
  25. Wu J, Wang X, Chiba H, Higuchi M, Nakatani T, Ezaki O, Cui H, Yamada K, Ishimi Y. Combined intervention of soy isoflavone and moderate exercise prevents body fat elevation and bone loss in ovariectomized mice. Metabolism 2004;53:942-8. https://doi.org/10.1016/j.metabol.2004.01.019
  26. Hertrampf T, Gruca MJ, Seibel J, Laudenbach U, Fritzemeier KH, Diel P. The bone-protective effect of the phytoestrogen genistein is mediated via ER ${\alpha}$-dependent mechanisms and strongly enhanced by physical activity. Bone 2007;40:1529-35. https://doi.org/10.1016/j.bone.2007.02.006
  27. Levis S, Strickman-Stein N, Ganjei-Azar P, Xu P, Doerge DR, Krischer J. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Arch Intern Med 2011;171:1363-9. https://doi.org/10.1001/archinternmed.2011.330
  28. Wang H, Murphy PA. Isoflavone content in commercial soybean foods. J Agric Food Chem 1994;42:1666-73. https://doi.org/10.1021/jf00044a016
  29. Davey RA, Hahn CN, May BK, Morris HA. Osteoblast gene expression in rat long bones: effects of ovariectomy and dihydrotestosterone on mRNA levels. Calcif Tissue Int 2000;67:75-9. https://doi.org/10.1007/s00223001100
  30. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M; Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 2005;23: 97-104.
  31. Taku K, Melby MK, Kurzer MS, Mizuno S, Watanabe S, Ishimi Y. Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials. Bone 2010;47:413-23. https://doi.org/10.1016/j.bone.2010.05.001
  32. Fu SW, Zeng GF, Zong SH, Zhang ZY, Zou B, Fang Y, Lu L, Xiao DQ. Systematic review and meta-analysis of the bone protective effect of phytoestrogens on osteoporosis in ovariectomized rats. Nutr Res 2014;34:467-77. https://doi.org/10.1016/j.nutres.2014.05.003
  33. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 2005;26:97-122.
  34. Vasikaran SD. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 2008;45:221-58. https://doi.org/10.1080/10408360801949442
  35. Miller PD, Hochberg MC, Wehren LE, Ross PD, Wasnich RD. How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005;21:545-53. https://doi.org/10.1185/030079905X41390
  36. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5. https://doi.org/10.1210/endo.142.12.8536
  37. Bateman TA, Countryman S. Osteoprotegerin and bone loss associated with spaceflight. Drug Discov Today 2002;7:456-7. https://doi.org/10.1016/S1359-6446(02)02260-2
  38. Brink E, Coxam V, Robins S, Wahala K, Cassidy A, Branca F; PHYTOS Investigator. Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study. Am J Clin Nutr 2008;87:761-70. https://doi.org/10.1093/ajcn/87.3.761
  39. Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, Holm-Jensen T. Soymilk or progesterone for prevention of bone loss-a 2 year randomized, placebo-controlled trial. Eur J Nutr 2004;43:246-57. https://doi.org/10.1007/s00394-004-0497-8
  40. Nikander E, Metsä-Heikkilä M, Ylikorkala O, Tiitinen A. Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer. J Clin Endocrinol Metab 2004;89:1207-12. https://doi.org/10.1210/jc.2003-031166
  41. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000;15:1337-45. https://doi.org/10.1359/jbmr.2000.15.7.1337
  42. Halleen JM. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 2003;23:1027-9.

Cited by

  1. Non-isoflavones Diet Incurred Metabolic Modifications Induced by Constipation in Rats via Targeting Gut Microbiota vol.9, pp.None, 2018, https://doi.org/10.3389/fmicb.2018.03002
  2. Bioavailability of Zinc in Rats Fed Soybeans Fortified with Zinc Via Foliar Spray vol.66, pp.8, 2019, https://doi.org/10.3136/nskkk.66.299
  3. Isoflavone-enriched whole soy milk powder stimulates osteoblast differentiation vol.58, pp.2, 2018, https://doi.org/10.1007/s13197-020-04572-6
  4. Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans vol.10, pp.7, 2021, https://doi.org/10.3390/antiox10071064